Clinical Trial: A Phase 2/3 Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia

U.S., March 3 -- ClinicalTrials.gov registry received information related to the study (NCT07441876) titled 'A Phase 2/3 Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia' on Feb. 11.

Brief Summary: This is a multicenter, multinational, randomized, active-controlled, operationally seamless Phase 2/3 study of BMN 333 in treatment-naive pediatric participants with achondroplasia (ACH). The study consists of a Phase 2 part and a Phase 3 part.

Study Start Date: Feb., 2026

Study Type: INTERVENTIONAL

Condition: Achondroplasia

Intervention: DRUG: BMN 333

Administration: Weekly subcutaneous injection

DRUG: Vosoritide Injection [Voxzogo]

Administration: Daily subcutaneous injection

Recr...